ProMIS Neurosciences Beta
What is the Beta of ProMIS Neurosciences?
The Beta of ProMIS Neurosciences, Inc. is 1.04
What is the definition of Beta?
BETA indicates whether a stock is more or less volatile than the market as a whole. A beta less than 1 indicates that the stock is less volatile than the market, while a beta more than 1 indicates that the stock is more volatile. Volatility is measured as the fluctuation of the price around the mean.
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
Beta of companies in the Health Care sector on OTC compared to ProMIS Neurosciences
What does ProMIS Neurosciences do?
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Companies with beta similar to ProMIS Neurosciences
- Shree Hari Chemicals Export has Beta of 1.04
- Bajaj & Investment has Beta of 1.04
- GHW International has Beta of 1.04
- Pharming N.V has Beta of 1.04
- Pharming N.V has Beta of 1.04
- abrdn Australia Equity Fund Inc has Beta of 1.04
- ProMIS Neurosciences has Beta of 1.04
- Theriva Biologics Inc has Beta of 1.04
- Bank of Hawaii has Beta of 1.04
- SEACOR Inc has Beta of 1.04
- Mercantile Bank has Beta of 1.04
- Sa Sa International has Beta of 1.04
- Bharat Forge has Beta of 1.04